Articles with public access mandates - Maurizio PellecchiaLearn more
Not available anywhere: 4
Lysine covalent antagonists of melanoma inhibitors of apoptosis protein
P Udompholkul, C Baggio, L Gambini, G Alboreggia, M Pellecchia
Journal of Medicinal Chemistry 64 (21), 16147-16158, 2021
Mandates: US National Institutes of Health
The quest for an effective treatment for an intractable cancer: established and novel therapies for pancreatic Adenocarcinoma
BA Quinn, NA Lee, TP Kegelman, P Bhoopathi, L Emdad, SK Das, ...
Advances in Cancer Research 127, 283-306, 2015
Mandates: US National Institutes of Health
Anti-glioma efficacy and mechanism of action of tripolinolate A from Tripolium pannonicum
W Chai, L Chen, XY Lian, Z Zhang
Planta Medica 84 (11), 786-794, 2018
Mandates: National Natural Science Foundation of China
High‐Throughput Screening and Fragment‐Based Design: General Considerations for Lead Discovery and Optimization
M Pellecchia
NMR of Biomolecules: Towards Mechanistic Systems Biology, 253-263, 2012
Mandates: US National Institutes of Health
Available somewhere: 122
Perspectives on NMR in drug discovery: a technique comes of age
M Pellecchia, I Bertini, D Cowburn, C Dalvit, E Giralt, W Jahnke, TL James, ...
Nature Reviews Drug Discovery 7 (9), 738-745, 2008
Mandates: US National Institutes of Health
Role of excitatory amino acid transporter‐2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics
K Kim, SG Lee, TP Kegelman, ZZ Su, SK Das, R Dash, S Dasgupta, ...
Journal of cellular physiology 226 (10), 2484-2493, 2011
Mandates: US National Institutes of Health
A survey of the anti-apoptotic Bcl-2 subfamily expression in cancer types provides a platform to predict the efficacy of Bcl-2 antagonists in cancer therapy
WJ Placzek, J Wei, S Kitada, D Zhai, JC Reed, M Pellecchia
Cell death & disease 1 (5), e40-e40, 2010
Mandates: US National Institutes of Health
Targeting the Bcl-2 family for cancer therapy
S Thomas, BA Quinn, SK Das, R Dash, L Emdad, S Dasgupta, XY Wang, ...
Expert opinion on therapeutic targets 17 (1), 61-75, 2013
Mandates: US National Institutes of Health
Targeting Mcl-1 for the therapy of cancer
BA Quinn, R Dash, B Azab, S Sarkar, SK Das, S Kumar, RA Oyesanya, ...
Expert opinion on investigational drugs 20 (10), 1397-1411, 2011
Mandates: US National Institutes of Health
Identification of a new JNK inhibitor targeting the JNK-JIP interaction site
JL Stebbins, SK De, T Machleidt, B Becattini, J Vazquez, C Kuntzen, ...
Proceedings of the National Academy of Sciences 105 (43), 16809-16813, 2008
Mandates: US National Institutes of Health
ADAR1 activation drives leukemia stem cell self-renewal by impairing Let-7 biogenesis
MA Zipeto, A Sadarangani, NPD Santos, L Balaian, HJ Chun, G Pineda, ...
Cell stem cell 19 (2), 177-191, 2016
Mandates: US National Institutes of Health, Canadian Institutes of Health Research …
Bcl-2 antiapoptotic family proteins and chemoresistance in cancer
S Maji, S Panda, SK Samal, O Shriwas, R Rath, M Pellecchia, L Emdad, ...
Advances in cancer research 137, 37-75, 2018
Mandates: US National Institutes of Health, Department of Biotechnology, India
A Pan-BCL2 inhibitor renders bone-marrow-resident human leukemia stem cells sensitive to tyrosine kinase inhibition
DJ Goff, A Sadarangani, HJ Chun, CL Barrett, M Krajewska, H Leu, ...
Cell stem cell 12 (3), 316-328, 2013
Mandates: US National Institutes of Health, Canadian Institutes of Health Research …
Bid-induced release of AIF from mitochondria causes immediate neuronal cell death
S Landshamer, M Hoehn, N Barth, S Duvezin-Caubet, G Schwake, ...
Cell Death & Differentiation 15 (10), 1553-1563, 2008
Mandates: US National Institutes of Health
Functional specialization in proline biosynthesis of melanoma
J De Ingeniis, B Ratnikov, AD Richardson, DA Scott, P Aza-Blanc, SK De, ...
Public Library of Science 7 (9), e45190, 2012
Mandates: US National Institutes of Health
Inhibition of Mcl-1 with the pan–Bcl-2 family inhibitor (–) BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia
R Pan, VR Ruvolo, J Wei, M Konopleva, JC Reed, M Pellecchia, ...
Blood, The Journal of the American Society of Hematology 126 (3), 363-372, 2015
Mandates: US National Institutes of Health
Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth
AG Remacle, VS Golubkov, SA Shiryaev, R Dahl, JL Stebbins, ...
Cancer research 72 (9), 2339-2349, 2012
Mandates: US National Institutes of Health
Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24–mediated toxicity
R Dash, B Azab, BA Quinn, X Shen, XY Wang, SK Das, M Rahmani, J Wei, ...
Proceedings of the National Academy of Sciences 108 (21), 8785-8790, 2011
Mandates: US National Institutes of Health
BI-97C1, an optically pure Apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (Bcl-2) family proteins
J Wei, JL Stebbins, S Kitada, R Dash, W Placzek, MF Rega, B Wu, ...
Journal of medicinal chemistry 53 (10), 4166-4176, 2010
Mandates: US National Institutes of Health
NMR-based approaches for the identification and optimization of inhibitors of protein–protein interactions
E Barile, M Pellecchia
Chemical reviews 114 (9), 4749-4763, 2014
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program